Herb-Drug Interaction Evaluation on Concomitant Administration of IME-9 and Gliclazide in Preclinical Diabetic Rats

ABSTRACT

Background: Diabetes mellitus is the third most prevalent cause of mortality and morbidity globally. Several complementary or alternative therapies currently used to treat diabetes mellitus. IME-9 is a polyherbal preparation used to treat diabetes and contains numerous phytoconstituents that can alter the cytochrome enzymes, mainly CYP2C8, 2B6, 2D6, 1A2, 2C9, 2C19, and 3A4. Gliclazide is a commonly prescribed antidiabetic drug metabolized primarily by the CYP2C9 and CYP2C19 enzymes. Thereby, it is postulated that the concomitant administration of IME-9 with Gliclazide therapy in diabetic patients may lead to HDI (Herb-Drug Interaction).Materials and Methods: In the Pharmacokinetic (PK) and Pharmacodynamic (PD) Herb-Drug Interaction (HDI) studies, GL was given to rats orally at 8.22 mg/kg, followed by administration of IME-9 at a dose of 132.24 mg/kg for 21 days. On the 1st day and after 21 days of the study period, in vivo PK/PD parameters were evaluated. In silico molecular docking studies were carried out (Autodock Vina1.2.3) to explore the binding affinity of the 46 major phytoconstituents present in IME 9 with the CYP2C9 and CYP2C19 enzymes. The toxicity was studied by MTT assay.Results: The PK analysis showed that co-administration of (IME-9+GL) for 21 days altered the PK parameters, increasing the Gliclazide (GL) bioavailability. This study throws light on the occurrence of hypoglycemia following the concomitant administration of (IME-9+GL) post 21 days in rats, leading to significant HDI, which may further lead to deleterious effects such as hypoglycemic coma. Furthermore, it was observed that the co-administration did not restore the body weight but restored the plasma TC and TG levels to normal. Histopathology studies revealed pathological alterations in the pancreas of diabetic control rats, while the treated rats (GL, IME-9) showed moderate degeneration with focal necrosis and atrophy in the islet of Langerhans. The in silico study confirms the critical involvement of the cytochrome enzymes in the observed HDI.Conclusion: This preclinical study can help to identify potential HDI and take the appropriate measures to improve clinical outcomes and reduce the associated adverse effects.

KEYWORDS

• Diabetes Mellitus
• Gliclazide
• HDI
• IME-9
• Pharmacodynamic
• Pharmacokinetic

Showing references and in-text citations exactly as published.

• DOI10.5530/ijper.20267022Copy

Copyright and licence

© 2026 Author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. CC BY 4.0

RELATED ARTICLES

Matched on section and article type within this issue of IJPER.

• Article · VOLUME 60, ISSUE 2Multidisciplinary Approach for Designing of Drug Delivery System: Leveraging Artificial Intelligence and Experimental Design for Enhanced Helicobacter pylori Formulation OptimizationManivasakam Prakash, Venkateswaramurthy Nallasamy, Senthil Venkatachalam, Anandharaj Govindaraj · pp. 485-493Original ArticleSame type: Article
• Article · VOLUME 60, ISSUE 2Innovative Exploration of the Connotation and Education and Training Practice Path of Outstanding Pharmaceutical EngineersJuan Chen, Yingying Ji, Hongliang Qian, Jiayu Li, Chunmeng Sun, Xinran Wang, Cheng Jiang · pp. 511-520Original ArticleSame type: Article
• Article · VOLUME 60, ISSUE 2Design Expert Optimization of Transdermal Patches for Effective Prolonged Release of Alzheimer's MedicationsBariki Rajasekhar, Haranath Chinthaginjala · pp. 521-531Original ArticleSame type: Article
• Article · VOLUME 60, ISSUE 2Formulation and Evaluation of Cilnidipine Loaded Nanoparticles for Enhanced SolubilityMahalingan Kuppan, Vedamurthy Joshi, Muhammad Shahzad Chohan, Nagaraja Sreeharsha · pp. 532-538Original ArticleSame type: Article